CAS NO:14192-26-8 PURITY:99.5% min
Synonyms:2-OXO-6-INDOLINECARBOXYLIC ACID METHYL ESTER;2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLIC ACID METHYL ESTER;2-INDOLINONE-6-METHYLCARBOXYLATE;6-METHOXYCARBONYL-2-OXINDOLE;METHYL 2-OXINDOLINE-6-CARBOXYLATE;METHYL 2-OXOINDOLINE-6-CARBOXYLATE;METHYL OXINDOLE-6-CARBOXYLATE;OXINDOLE-6-CARBOXYLIC ACID METHYL ESTER
Shangdong Shinning Pharm Co.,Ltd. is located in Taishan Road, Ningyang Economic Development Zone, Tai'an, Shandong. Shinning Pharm dedicates itself on research, develop and industrialize of intermediates and non-infringed synthetic route, serves global customers with high-class products and technologies, based on the professional develop ability and excellent business philosophy.
With the support of national, provincial and district government, Shangdong Shinning has achieved more than 100% annual growth rate since its foundation to a group incorporating 3 wholly-owned subsidiaries: Jinnan Xuande - 1000m2 - research institute with 50L and 100L reactor, 100L hydrogenation reactor and other instruments, Shandong Shinning 30000m2 -PLANT With 500L, 1000L, 2000L, 5000L reactor and vacuum pump, Taizhou Crene 200m2 for chemical reagents and kinase inhibitors warehouse.
The company will be a great pharmaceutical corporation with complete industry chain of research, development, production and marketing. Shangdong Shinning invested not less than 30 percent of annual revenue in research and development study, and R&D personnel account for near 70% of total 200 employees. The research institute has acquired HPLC, introduced state-of-the-art equipment such as NMR, LC-MS and AAS, and established the research platforms for multi-chiral, semi-synthetic APIs and Intermedaites. etc. The company has files 20 patent applications, 1 of them is authorized and Hope more in future.
Shangdong Shinning Pharm Co.,Ltd. mainly produces pharmaceutical intermediates, such as Idelalisib intermediates 870281-86-0, Tedizolid intermediates 856866-72-3, Afatinib intermediates 314771-76-1, Nintedanib intermediates 1168150-46-6, Lenvatinib intermediates 205448-66-4etc.,to provide customers with high quality and reasonable prices.
On the strength of excellent research and project management capability, our company provides comprehensive services for global market. Shangdong Shinning has successfully supported Chia Tai Tianqing Pharmaceutical Group to develop the Nintedanib & Idelalisib intermedaite in domestic market, by non-infringed synthetic route. Not only solutions for multi-steps, multi-chiral intermedaites, Shangdong Shinning provides independent process, analytical method development, Furthermore, our company is skilled in small molecule area, including process development, scale-up and purification.